Literature DB >> 33030305

Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy.

Guowei Wang1,2, Bihan Wu2, Qunying Li1, Siqin Chen2, Xiaoqin Jin3, Yajing Liu1, Zhuxian Zhou2,4, Youqing Shen4, Pintong Huang1.   

Abstract

Liposomes are the first and mostly explored nanocarriers for cancer drug delivery, which have shown great promise in clinical applications, but their limited accumulation and penetration into the tumor interstitial space, significantly reduce the therapeutic efficacy. Here, a γ-glutamyltranspeptidase (GGT)-triggered charge-switchable approach is reported that can trigger the fast endocytosis and transcytosis of the liposome in tumor microenvironments to overcome the harsh biological barriers in tumor tissues. The active transporting liposomal nanocarrier (GCSDL) is prepared by surface modification with a glutathione (GSH) moiety and encapsulated with doxorubicin (DOX). When the GCSDL contacts with tumor vascular endothelial cells, the overexpressed GGT enzyme on cytomembrane catalyzes the hydrolysis of GSH to generate cationic primary amines. The cationic GCSDL triggers fast caveolae-mediated endocytosis and vesicle-mediated transcytosis, resulting in sequential transcytosis to augment its tumor accumulation and penetration. Along with continual intercellular transportation, GCSDL can release DOX throughout the tumor to induce cancer cell apoptosis, resulting in complete eradication of hepatocellular carcinoma and cessation of pancreatic ductal adenocarcinoma's progression. This study develops an efficient strategy to realize high tumor accumulation and deep penetration for the liposomal drug delivery system via active transcytosis.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  cancer drug delivery; liposome; transcytosis; tumor accumulation and penetration; γ-glutamyltranspeptidase

Mesh:

Substances:

Year:  2020        PMID: 33030305     DOI: 10.1002/smll.202004172

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  13 in total

Review 1.  Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.

Authors:  Khaled Mahmoud; Shady Swidan; Mohamed El-Nabarawi; Mahmoud Teaima
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

Review 2.  Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy.

Authors:  Yilei Lu; Siqi Wang; Yuhang Wang; Mingshan Li; Yili Liu; Dongwei Xue
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

3.  Cavitation assisted endoplasmic reticulum targeted sonodynamic droplets to enhanced anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Jifan Chen; Liting Feng; Peile Jin; Jiaxin Shen; Jiayue Lu; Yue Song; Guowei Wang; Qin Chen; Deyi Huang; Ying Zhang; Chao Zhang; Youfeng Xu; Pintong Huang
Journal:  J Nanobiotechnology       Date:  2022-06-16       Impact factor: 9.429

Review 4.  Recent progress in nanomedicine for enhanced cancer chemotherapy.

Authors:  Guoqing Wei; Yu Wang; Guang Yang; Yi Wang; Rong Ju
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

Review 5.  Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.

Authors:  Yitong Li; Ruihang Zhang; Zhen Xu; Zhicheng Wang
Journal:  Int J Nanomedicine       Date:  2022-02-26

Review 6.  Drug delivery strategy in hepatocellular carcinoma therapy.

Authors:  Sisi Yang; Chengwei Cai; Huanqiu Wang; Xueqing Ma; Anwen Shao; Jifang Sheng; Chengbo Yu
Journal:  Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.712

Review 7.  Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.

Authors:  Amin Mehrabian; Mohammad Mashreghi; Saba Dadpour; Ali Badiee; Leila Arabi; Seyedeh Hoda Alavizadeh; Seyedeh Alia Moosavian; Mahmoud Reza Jaafari
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

8.  A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy.

Authors:  Jiahui Peng; Fangman Chen; Yulu Liu; Fan Zhang; Lei Cao; Qiannan You; Dian Yang; Zhimin Chang; Mingfeng Ge; Li Li; Zheng Wang; Qian Mei; Dan Shao; Meiwan Chen; Wen-Fei Dong
Journal:  Theranostics       Date:  2022-01-24       Impact factor: 11.556

Review 9.  Dendrimer-based drug delivery systems: history, challenges, and latest developments.

Authors:  Juan Wang; Boxuan Li; Li Qiu; Xin Qiao; Hu Yang
Journal:  J Biol Eng       Date:  2022-07-25       Impact factor: 6.248

10.  Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.

Authors:  Aixue Li; Yunan Zhao; Yixiu Li; Liangdi Jiang; Yongwei Gu; Jiyong Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.